News ArchivesRead News
Parkinson’s Disease - Should We Start Being Genetically Tested For It?
Thursday December 15, 2005
11 Dec 2005(Medical News Today) - Should we start being genetically tested for Parkinson’s disease (PD)? According to research just published in the December issue of the "journal Movement Disorders" this might be a possibility in the future if you belong to a family affected by G2019S, a genetic mutation responsible for some PD cases.
Parkinson disease results from the death or loss of function of the nervous cells (neurons) in a brain area called substancia nigra, which is involved in the regulation of movement. Neurons within this region produce dopamine, a neurotransmitter that acts as messenger between the substancia nigra (the control centre) and other neurons around the body, leading to a correct regulation of the body movements. If the substancia nigra degenerates, like it happens in PD, dopamine is no longer properly produced and the individual starts presenting the typical symptoms of Parkinson’s disease such as slowed movements, tremors, loss of movement control and rigidity.
Although there is still no cure, treatments, which increase the brain’s dopamine levels, are relatively effective. Unfortunately, as disease progresses, treatment becomes less and less efficient and the patient’s full deterioration is inevitable. The disease affects about 1% of the world population with, only in the US, half a million people affected and about 50,000 new cases are reported every year, a number predicted to increase as the average age of the populations also increases.
In fact, among the risks factors for PD, advanced age is the most important with more than 3% of the population above 65 years old affected. In a society where life expectancy has been increasing consistently, especially in the developed world, this situation can lead to major health and economic problems emphasising the urgency to understand better the disease.
Additionally, environmental factors also seem to have an important role in the regulation of PD although which factors, is still not clear. But it is believed that toxins, slowly accumulated over time, can induce disease. One example of this effect was the observation that MPTP (a by-product of synthetic heroin), which in the 80s was sold in the streets by mistake, was able to induce severe end stage parkinsonian symptoms in several young drug abusers as result of specific destruction of the substancia nigra, as later found by autopsy. Another example is the observation that PD incidence is much higher in rural areas what have led researchers to propose that toxins in herbicides or pesticides may cause or contribute to the disease. Interestingly, both caffeine consumption and smoking seem to diminish disease incidence.
Furthermore, individuals with a family history of PD also have a higher chance of suffering from the disease. Indeed, although for a long time favoured as an environmental triggered disease, in the last decade researchers have identified several (five so far) genes, which when mutated can lead to PD.
Nevertheless, until very recently the number and importance of the cases resulting from genetic mutations was considered too low to be relevant in the overall disease panorama. This idea only started to change with the last discovered gene, LRRK2. In fact, LRRK2 mutations seem be particularly frequent accounting for 3 -6% of PD familial cases (when the mutation in inherited and so found within families in more than one individual) and around 2% of PD sporadic cases (when the mutation occurs occasionally in a random and isolated manner). These high numbers have led to a series of studies investigating the gene and its mutations in order to understand better the epidemiological importance of LRRK2.
José Miguel Bras, Rita João Guerreiro, Andrew Singleton and colleagues from Portugal and the USA decided to investigate, in a Portuguese group of 128 patients and 1400 healthy individuals, what they previously found to be the two most common LRRK2 mutations. They discovered that while one of the mutations could not be found among their patients, the other, called G2019S, was found in a remarkably high number of individuals - about 6% of the total number of patients. Very interestingly, it was also found that all the individuals with G2019S suffered from disease, while none of the healthy controls had the mutation. This suggests that G2019S is a pathogenic mutation, meaning that when it occurs in an individual it will always result in disease, in contrast with other mutations where only a fraction of the affected individuals will suffer from the illness. This conclusion was supported by previous research by the same scientists, which showed the same disease pattern in two American families with G2019S, and again a total absence of the mutation in more than 1500 healthy controls this time from the US.
Guerreiro, Singleton and colleagues’ work is important not only because it helps to understand better the dynamics of PD, but because it raises the issue of genetic testing for Parkinson’s disease among G2019S affected families or even high-risk populations. In fact, not only G2019S seems to be present in a high number of PD patients, but also is a pathogenic mutation that will lead to disease sooner or later. Genetic testing of a non-curable fatal disease is not an easy option but, although there is still no cure for Parkinson’s disease, early diagnosis and consequent treatment might result in a longer healthier life and in this sense might be a wise, even if difficult, choice for patients
Recent NewsNov 17 - 'Moving Day' participant is not letting young-onset Parkinson's disease stop him
Nov 17 - Focused ultrasound shows promise for treating Parkinson's tremor
Nov 17 - New research to target air pollution as a potential trigger for Parkinson’s
Nov 17 - This device will let you feel what it's like to suffer from Parkinson's
Nov 10 - How does Parkinson's disease influence depression?
Nov 10 - House votes to repeal ObamaCare's Medicare cost-cutting board
Nov 10 - Microsoft shows off watch that quiets Parkinson's tremors
Nov 3 - Utah group battling Parkinson's disease with boxing
Nov 3 - UVA-LED STUDY EXAMINES POTENTIAL OF SOUND WAVES TO MANAGE PARKINSON’S DISEASE
Oct 27 - Herbicide's link to Parkinson's disease
Oct 27 - NTU Singapore, KAIST scientists discover new mechanism that causes Parkinsonian symptoms
Oct 27 - 70,000 Washingtonians face higher insurance costs after Trump order, officials say
Oct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 18 - Fighting Parkinson's disease through dance
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests